Meta-analysis - Eltrombopag
Sponsor
GlaxoSmithKline (Industry)
Overall Status
Completed
CT.gov ID
NCT01235988
Collaborator
(none)
1
2
Study Details
Study Description
Brief Summary
The purpose of the meta-analysis was to explore the efficacy of eltrombopag versus placebo (standard of care)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Meta-analysis of three studies: Bussell 2007 & Bussell 2009 & RAISE (TRA102537).
Study Design
Study Type:
Observational
Actual Enrollment
:
1 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Systematic Review of the Clinical and Cost Effectiveness of Treatments for Idiopathic (Immune) Thrombocytopenic Purpura (ITP): Direct Meta Analysis
Study Start Date
:
Aug 1, 2009
Actual Primary Completion Date
:
Oct 1, 2009
Actual Study Completion Date
:
Oct 1, 2009
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Eltrombopag & standard of care
|
Drug: Eltrombopag
Eltrombopag 50mg & standard of care
|
| Standard of care
|
Drug: Placebo
Placebo + standard of care
|
Outcome Measures
Primary Outcome Measures
- >=50 Gi/L platelet count to <400 Gi/L [43 days]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Adults with ITP
-
Received a pre-specified treatment
-
Prospective clinical studies with at least 10 patients
Exclusion Criteria:
- Subjects with ITP due to other causes
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- GlaxoSmithKline
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01235988
Other Study ID Numbers:
- 114013
First Posted:
Nov 7, 2010
Last Update Posted:
Jun 7, 2017
Last Verified:
Jun 1, 2017
Additional relevant MeSH terms: